Affiliation:
1. Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, New Jersey
2. Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio
Abstract
ABSTRACT
In phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1,219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates, including methicillin-resistant strains, at MICs of ≤4 μg/ml. Against
Enterobacteriaceae
and
Pseudomonas aeruginosa
isolates, the potency of ceftobiprole was similar to that of cefepime.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献